Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alvotech SA ALVO

Healthcare Biotechnology
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating... see more

Recent & Breaking News (NDAQ:ALVO)

STADA and Alvotech secure approval for Uzpruvo, Europe's first ustekinumab biosimilar to Stelara

GlobeNewswire January 10, 2024

Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)

GlobeNewswire January 3, 2024

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

GlobeNewswire November 29, 2023

Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

GlobeNewswire November 28, 2023

Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET

GlobeNewswire November 21, 2023

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki(TM) (AVT04), the First Biosimilar of Stelara® (ustekinumab)

GlobeNewswire November 14, 2023

STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab biosimilar to Stelara

GlobeNewswire November 10, 2023

Alvotech to Present at the Jefferies 2023 London Healthcare Conference

GlobeNewswire November 7, 2023

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

GlobeNewswire October 12, 2023

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

Business Wire October 3, 2023

Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

GlobeNewswire October 3, 2023

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

GlobeNewswire September 25, 2023

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

GlobeNewswire September 20, 2023

Alvotech Announces Changes to the Leadership Team

GlobeNewswire September 5, 2023

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

GlobeNewswire August 30, 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

GlobeNewswire August 29, 2023

Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET

GlobeNewswire August 22, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

Accesswire August 18, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm

Accesswire August 8, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire August 3, 2023